In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovant Gene Therapies Ltd.

Division of Roivant Sciences Inc.
www.axovant.com

Latest From Axovant Gene Therapies Ltd.

Interview: Arvelle Aims To Be Major Player In CNS

The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.

Neurology Business Strategies

Oxford Biomedica Transforms With New Deals, R&D Pipeline, And Manufacturing Facilities

The lentivirus gene delivery company, Oxford Biomedica, is to collaborate with Juno Therapeutics on its CAR-T and TCR-T projects, adding to the UK biotech’s transformation into a debt-free company with a growing in-house product pipeline.

Deals Gene Therapy

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Financing Business Strategies

Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned

A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Axovant Sciences Ltd.
  • Roivant Neurosciences Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Roivant Sciences Inc.
  • Senior Management
  • Pavan Cheruvu, MD, CEO
    David Nassif, CFO
    Fraser Wright, PhD, CTO
    Shankar Ramaswamy, MD, Chief Business Officer
    Gavin Corcoran, MD, EVP, R&D
    Ilise Lombardo, MD, CMO
    Paul Korner, MD, SVP, Clin. Dev.
  • Contact Info
  • Axovant Gene Therapies Ltd.
    Phone: 1-295-5950
    20-22 Bedford Row
    London, X0 WC1R 4J
    UK
UsernamePublicRestriction

Register